Epigenetic Dysregulation in Thyroid Neoplasia

Endocrinology and Metabolism Clinics of North America

Volumn 37, Issue 2, 2008, Pages 389-400

  Kondo, Tetsuo ^a   Asa, Sylvia L ^b,c   Ezzat, Shereen ^b,c  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; LEVOTHYROXINE; LIOTHYRONINE; MITOGEN ACTIVATED PROTEIN KINASE; PENDRIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; THYROID HORMONE; THYROID PEROXIDASE; THYROTROPIN;

CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; HISTOLOGY; HORMONE RELEASE; HUMAN; PRIORITY JOURNAL; REVIEW; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; TUMOR SUPPRESSOR GENE; UNDIFFERENTIATED CARCINOMA;

CARCINOMA; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, BIOLOGICAL; ONCOGENES; ORGAN SPECIFICITY; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 43849091921     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.12.002     Document Type: Review

References (61)

1. Kondo T., Zhu X., Asa S.L., et al. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin Cancer Res 13 (2007) 4713-4720
2. Ozawa H., and Iwatsuki K. Pharmacological properties of heterocyclic amidine derivatives. II. Pharmacological studies of phenylguanylpiperazine derivatives. Chem Pharm Bull (Tokyo) 16 (1968) 2482-2487
3. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 148 (2007) 948-953
4. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 Spec No 1 (2007) R50-R59
5. Feinberg A.P., and Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301 (1983) 89-92
6. Zhu X., Lee K., Asa S.L., et al. Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol 170 (2007) 1618-1628
7. Fabbro D., Di Loreto C., Beltrami C.A., et al. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 54 (1994) 4744-4749
8. Gerard A.C., Daumerie C., Mestdagh C., et al. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. J Clin Endocrinol Metab 88 (2003) 4977-4983
9. Kondo T., Nakamura N., Suzuki K., et al. Expression of human pendrin in diseased thyroids. J Histochem Cytochem 51 (2003) 167-173
10. Mizukami Y., Hashimoto T., Nonomura A., et al. Immunohistochemical demonstration of thyrotropin (TSH)-receptor in normal and diseased human thyroid tissues using monoclonal antibody against recombinant human TSH-receptor protein. J Clin Endocrinol Metab 79 (1994) 616-619
11. Maxon H.R., Thomas S.R., Hertzberg V.S., et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309 (1983) 937-941
12. Xing M., Usadel H., Cohen Y., et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 63 (2003) 2316-2321
13. Neumann S., Schuchardt K., Reske A., et al. Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules. Thyroid 14 (2004) 99-111
14. Venkataraman G.M., Yatin M., Marcinek R., et al. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 84 (1999) 2449-2457
15. Kondo T., Ezzat S., and Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6 (2006) 292-306
16. Durante C., Puxeddu E., Ferretti E., et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92 (2007) 2840-2843
17. Liu D., Hu S., Hou P., et al. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 13 (2007) 1341-1349
18. Khoo M.L., Beasley N.J., Ezzat S., et al. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 87 (2002) 1814-1818
19. Elisei R., Shiohara M., Koeffler H.P., et al. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 83 (1998) 2185-2193
20. Donninger H., Vos M.D., and Clark G.J. The RASSF1A tumor suppressor. J Cell Sci 120 (2007) 3163-3172
21. Dammann R., Schagdarsurengin U., Strunnikova M., et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 18 (2003) 665-677
22. Nakamura N., Carney J.A., Jin L., et al. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest 85 (2005) 1065-1075
23. Xing M., Cohen Y., Mambo E., et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 64 (2004) 1664-1668
24. Schagdarsurengin U., Gimm O., Hoang-Vu C., et al. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62 (2002) 3698-3701
25. Ezzat S., and Asa S.L. FGF receptor signaling at the crossroads of endocrine homeostasis and tumorigenesis. Horm Metab Res 37 (2005) 355-360
26. St Bernard R., Zheng L., Liu W., et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146 (2005) 1145-1153
27. Kondo T., Zheng L., Liu W., et al. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 67 (2007) 5461-5470
28. Liu W., Wei W., Winer D., et al. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 26 (2007) 2747-2758
29. Brabant G., Hoang-Vu C., Cetin Y., et al. E-cadherin: a differentiation marker in thyroid malignancies. Cancer Res 53 (1993) 4987-4993
30. Kato N., Tsuchiya T., Tamura G., et al. E-cadherin expression in follicular carcinoma of the thyroid. Pathol Int 52 (2002) 13-18
31. Scheumman G.F., Hoang-Vu C., Cetin Y., et al. Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas. J Clin Endocrinol Metab 80 (1995) 2168-2172
32. Soares P., Berx G., van Roy F., et al. E-cadherin gene alterations are rare events in thyroid tumors. Int J Cancer 70 (1997) 32-38
33. Rocha A.S., Soares P., Seruca R., et al. Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant. J Pathol 194 (2001) 358-366
34. Xiao J., and Chen H.S. Biological functions of melanoma-associated antigens. World J Gastroenterol 10 (2004) 1849-1853
35. van der B.P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
36. Milkovic M., Sarcevic B., and Glavan E. Expression of MAGE tumor-associated antigen in thyroid carcinomas. Endocr Pathol 17 (2006) 45-52
37. Yang B., O'Herrin S., Wu J., et al. Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol 127 (2007) 267-275
38. Monte M., Simonatto M., Peche L.Y., et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 103 (2006) 11160-11165
39. Yang B., O'Herrin S.M., Wu J., et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 67 (2007) 9954-9962
40. DeLellis R.A., Lloyd R.V., Heitz P.U., et al. Pathology and genetics of tumours of endocrine organs. WHO classification of tumours (2004), IARC Press, Lyons (France)
41. Hirokawa M., Carney J.A., Goellner J.R., et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 26 (2002) 1508-1514
42. Lloyd R.V., Erickson L.A., Casey M.B., et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28 (2004) 1336-1340
43. Huang Y., Prasad M., Lemon W.J., et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 98 (2001) 15044-15049
44. Wasenius V.M., Hemmer S., Kettunen E., et al. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 9 (2003) 68-75
45. Cheung C.C., Ezzat S., Freeman J.L., et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14 (2001) 338-342
46. Prasad M.L., Pellegata N.S., Huang Y., et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18 (2005) 48-57
47. Tuncel M., Aydin D., Yaman E., et al. The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake. Cancer Biother Radiopharm 22 (2007) 281-288
48. Furuya F., Shimura H., Suzuki H., et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145 (2004) 2865-2875
49. Kitazono M., Robey R., Zhan Z., et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86 (2001) 3430-3435
50. Zarnegar R., Brunaud L., Kanauchi H., et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132 (2002) 984-990
51. Park W.H., Jung C.W., Park J.O., et al. Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis. Int J Oncol 22 (2003) 1129-1134
52. Platta C.S., Greenblatt D.Y., Kunnimalaiyaan M., et al. The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res 142 (2007) 219-226
53. Wang Z.M., Hu J., Zhou D., et al. Trichostatin A inhibits proliferation and induces expression of p21WAF and p27 in human brain tumor cell lines. Ai Zheng 21 (2002) 1100-1105
54. Greenberg V.L., Williams J.M., Boghaert E., et al. Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells. Thyroid 11 (2001) 21-29
55. Greenberg V.L., Williams J.M., Cogswell J.P., et al. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. Thyroid 11 (2001) 315-325
56. Mitsiades C.S., Poulaki V., McMullan C., et al. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 11 (2005) 3958-3965
57. Dackiw A.P., Ezzat S., Huang P., et al. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 145 (2004) 5840-5846
58. Khoo M.L., Freeman J.L., Witterick I.J., et al. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg 128 (2002) 253-257
59. Liu W., Asa S.L., Fantus I.G., et al. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through pten/akt-dependent and-independent pathways. Am J Pathol 160 (2002) 511-519
60. Wischnewski F., Pantel K., and Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 4 (2006) 339-349
61. Appleton K., Mackay H.J., Judson I., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25 (2007) 4603-4609